Loading…
Cyclosporin in the treatment of adults with refractory coeliac disease—an open pilot study
Aim: To evaluate the effect of cyclosporin treatment on clinical and histological parameters in adult patients with refractory coeliac disease. Methods: Thirteen patients were treated with oral cyclosporin for 2 months, aiming at serum levels of 100–200 ng/mL. Seven extended medication intake up to...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2000-06, Vol.14 (6), p.767-774 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13 |
| container_end_page | 774 |
| container_issue | 6 |
| container_start_page | 767 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 14 |
| creator | WAHAB, P. J CRUSIUS, J. B. A MEIJER, J. W. R UIL, J. J MULDER, C. J. J |
| description | Aim:
To evaluate the effect of cyclosporin treatment on clinical and histological parameters in adult patients with refractory coeliac disease.
Methods:
Thirteen patients were treated with oral cyclosporin for 2 months, aiming at serum levels of 100–200 ng/mL. Seven extended medication intake up to a maximum of 12 months. Before and after treatment, clinical parameters were monitored and small intestinal biopsies taken. Ten of 13 patients were typed for HLA‐DQA1 and ‐DQB1 alleles.
Results:
Eight of 13 patients responded histologically to cyclosporin treatment. Normalization of villi was demonstrated in five patients, three after prolonged treatment. Eight patients reported a clinical response, of whom six had concomitant histological improvement. No serious side‐effects of cyclosporin were noticed. Nine of 10 patients who were immunogenetically typed carried the coeliac disease associated serologic DQ2 markers, one carried neither DQ2 nor DQ8 markers.
Conclusion:
In our study group of 13 adult refractory coeliac disease patients, cyclosporin in therapeutic doses induced a histological improvement in eight patients (61%), in five of whom (38%) normalization of villi was demonstrated. Thus, we believe that cyclosporin is a therapeutic option in refractory coeliac disease, although we could not confirm earlier reports of unconditional successful treatment. |
| doi_str_mv | 10.1046/j.1365-2036.2000.00718.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71181714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71181714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13</originalsourceid><addsrcrecordid>eNqNkM2KFDEQgIMo7rj6CpKDeOu28tPpNHhZhvUHFvSw3oSQSdJshkynTdLs9s2H8Al9EjPOoB6Fgiqor6qoDyFMoCXAxZt9S5joGgpMtBQAWoCeyPbhEdr8aTxGG6BiaKgk7AI9y3lfQdEDfYouCEguhSAb9HW7mhDzHJOfcI1y53BJTpeDmwqOI9Z2CSXje1_ucHJj0qbEtGITXfDaYOuz09n9_P5DTzjObsKzD7HgXBa7PkdPRh2ye3HOl-jLu-vb7Yfm5tP7j9urm8bwnspGUmNIt-sN4VqPPSfMdb2gHVAQlIlxZ7iz1podEzBwY0EbDQODzthRgiXsEr0-7Z1T_La4XNTBZ-NC0JOLS1Y9IZL0hFdQnkCTYs71HTUnf9BpVQTU0azaq6NAdRSojmbVb7PqoY6-PN9Ydgdn_xk8qazAqzOgs9GhmpqMz385NnA-yIq9PWH3Prj1v--rq8-3tWC_AJbYlbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71181714</pqid></control><display><type>article</type><title>Cyclosporin in the treatment of adults with refractory coeliac disease—an open pilot study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>WAHAB, P. J ; CRUSIUS, J. B. A ; MEIJER, J. W. R ; UIL, J. J ; MULDER, C. J. J</creator><creatorcontrib>WAHAB, P. J ; CRUSIUS, J. B. A ; MEIJER, J. W. R ; UIL, J. J ; MULDER, C. J. J</creatorcontrib><description>Aim:
To evaluate the effect of cyclosporin treatment on clinical and histological parameters in adult patients with refractory coeliac disease.
Methods:
Thirteen patients were treated with oral cyclosporin for 2 months, aiming at serum levels of 100–200 ng/mL. Seven extended medication intake up to a maximum of 12 months. Before and after treatment, clinical parameters were monitored and small intestinal biopsies taken. Ten of 13 patients were typed for HLA‐DQA1 and ‐DQB1 alleles.
Results:
Eight of 13 patients responded histologically to cyclosporin treatment. Normalization of villi was demonstrated in five patients, three after prolonged treatment. Eight patients reported a clinical response, of whom six had concomitant histological improvement. No serious side‐effects of cyclosporin were noticed. Nine of 10 patients who were immunogenetically typed carried the coeliac disease associated serologic DQ2 markers, one carried neither DQ2 nor DQ8 markers.
Conclusion:
In our study group of 13 adult refractory coeliac disease patients, cyclosporin in therapeutic doses induced a histological improvement in eight patients (61%), in five of whom (38%) normalization of villi was demonstrated. Thus, we believe that cyclosporin is a therapeutic option in refractory coeliac disease, although we could not confirm earlier reports of unconditional successful treatment.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.2000.00718.x</identifier><identifier>PMID: 10848661</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Celiac Disease - drug therapy ; Celiac Disease - pathology ; Cyclosporine - pharmacology ; Cyclosporine - therapeutic use ; Female ; Humans ; Immunomodulators ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Intestinal Mucosa - drug effects ; Intestinal Mucosa - ultrastructure ; Intestine, Small - drug effects ; Intestine, Small - pathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pilot Projects ; Recurrence ; Treatment Outcome</subject><ispartof>Alimentary pharmacology & therapeutics, 2000-06, Vol.14 (6), p.767-774</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13</citedby><cites>FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1394498$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10848661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WAHAB, P. J</creatorcontrib><creatorcontrib>CRUSIUS, J. B. A</creatorcontrib><creatorcontrib>MEIJER, J. W. R</creatorcontrib><creatorcontrib>UIL, J. J</creatorcontrib><creatorcontrib>MULDER, C. J. J</creatorcontrib><title>Cyclosporin in the treatment of adults with refractory coeliac disease—an open pilot study</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aim:
To evaluate the effect of cyclosporin treatment on clinical and histological parameters in adult patients with refractory coeliac disease.
Methods:
Thirteen patients were treated with oral cyclosporin for 2 months, aiming at serum levels of 100–200 ng/mL. Seven extended medication intake up to a maximum of 12 months. Before and after treatment, clinical parameters were monitored and small intestinal biopsies taken. Ten of 13 patients were typed for HLA‐DQA1 and ‐DQB1 alleles.
Results:
Eight of 13 patients responded histologically to cyclosporin treatment. Normalization of villi was demonstrated in five patients, three after prolonged treatment. Eight patients reported a clinical response, of whom six had concomitant histological improvement. No serious side‐effects of cyclosporin were noticed. Nine of 10 patients who were immunogenetically typed carried the coeliac disease associated serologic DQ2 markers, one carried neither DQ2 nor DQ8 markers.
Conclusion:
In our study group of 13 adult refractory coeliac disease patients, cyclosporin in therapeutic doses induced a histological improvement in eight patients (61%), in five of whom (38%) normalization of villi was demonstrated. Thus, we believe that cyclosporin is a therapeutic option in refractory coeliac disease, although we could not confirm earlier reports of unconditional successful treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Celiac Disease - drug therapy</subject><subject>Celiac Disease - pathology</subject><subject>Cyclosporine - pharmacology</subject><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestinal Mucosa - ultrastructure</subject><subject>Intestine, Small - drug effects</subject><subject>Intestine, Small - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Recurrence</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqNkM2KFDEQgIMo7rj6CpKDeOu28tPpNHhZhvUHFvSw3oSQSdJshkynTdLs9s2H8Al9EjPOoB6Fgiqor6qoDyFMoCXAxZt9S5joGgpMtBQAWoCeyPbhEdr8aTxGG6BiaKgk7AI9y3lfQdEDfYouCEguhSAb9HW7mhDzHJOfcI1y53BJTpeDmwqOI9Z2CSXje1_ucHJj0qbEtGITXfDaYOuz09n9_P5DTzjObsKzD7HgXBa7PkdPRh2ye3HOl-jLu-vb7Yfm5tP7j9urm8bwnspGUmNIt-sN4VqPPSfMdb2gHVAQlIlxZ7iz1podEzBwY0EbDQODzthRgiXsEr0-7Z1T_La4XNTBZ-NC0JOLS1Y9IZL0hFdQnkCTYs71HTUnf9BpVQTU0azaq6NAdRSojmbVb7PqoY6-PN9Ydgdn_xk8qazAqzOgs9GhmpqMz385NnA-yIq9PWH3Prj1v--rq8-3tWC_AJbYlbA</recordid><startdate>200006</startdate><enddate>200006</enddate><creator>WAHAB, P. J</creator><creator>CRUSIUS, J. B. A</creator><creator>MEIJER, J. W. R</creator><creator>UIL, J. J</creator><creator>MULDER, C. J. J</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200006</creationdate><title>Cyclosporin in the treatment of adults with refractory coeliac disease—an open pilot study</title><author>WAHAB, P. J ; CRUSIUS, J. B. A ; MEIJER, J. W. R ; UIL, J. J ; MULDER, C. J. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Celiac Disease - drug therapy</topic><topic>Celiac Disease - pathology</topic><topic>Cyclosporine - pharmacology</topic><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestinal Mucosa - ultrastructure</topic><topic>Intestine, Small - drug effects</topic><topic>Intestine, Small - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Recurrence</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WAHAB, P. J</creatorcontrib><creatorcontrib>CRUSIUS, J. B. A</creatorcontrib><creatorcontrib>MEIJER, J. W. R</creatorcontrib><creatorcontrib>UIL, J. J</creatorcontrib><creatorcontrib>MULDER, C. J. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WAHAB, P. J</au><au>CRUSIUS, J. B. A</au><au>MEIJER, J. W. R</au><au>UIL, J. J</au><au>MULDER, C. J. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cyclosporin in the treatment of adults with refractory coeliac disease—an open pilot study</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2000-06</date><risdate>2000</risdate><volume>14</volume><issue>6</issue><spage>767</spage><epage>774</epage><pages>767-774</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aim:
To evaluate the effect of cyclosporin treatment on clinical and histological parameters in adult patients with refractory coeliac disease.
Methods:
Thirteen patients were treated with oral cyclosporin for 2 months, aiming at serum levels of 100–200 ng/mL. Seven extended medication intake up to a maximum of 12 months. Before and after treatment, clinical parameters were monitored and small intestinal biopsies taken. Ten of 13 patients were typed for HLA‐DQA1 and ‐DQB1 alleles.
Results:
Eight of 13 patients responded histologically to cyclosporin treatment. Normalization of villi was demonstrated in five patients, three after prolonged treatment. Eight patients reported a clinical response, of whom six had concomitant histological improvement. No serious side‐effects of cyclosporin were noticed. Nine of 10 patients who were immunogenetically typed carried the coeliac disease associated serologic DQ2 markers, one carried neither DQ2 nor DQ8 markers.
Conclusion:
In our study group of 13 adult refractory coeliac disease patients, cyclosporin in therapeutic doses induced a histological improvement in eight patients (61%), in five of whom (38%) normalization of villi was demonstrated. Thus, we believe that cyclosporin is a therapeutic option in refractory coeliac disease, although we could not confirm earlier reports of unconditional successful treatment.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>10848661</pmid><doi>10.1046/j.1365-2036.2000.00718.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2000-06, Vol.14 (6), p.767-774 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71181714 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Aged Biological and medical sciences Celiac Disease - drug therapy Celiac Disease - pathology Cyclosporine - pharmacology Cyclosporine - therapeutic use Female Humans Immunomodulators Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Intestinal Mucosa - drug effects Intestinal Mucosa - ultrastructure Intestine, Small - drug effects Intestine, Small - pathology Male Medical sciences Middle Aged Pharmacology. Drug treatments Pilot Projects Recurrence Treatment Outcome |
| title | Cyclosporin in the treatment of adults with refractory coeliac disease—an open pilot study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T22%3A57%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cyclosporin%20in%20the%20treatment%20of%20adults%20with%20refractory%20coeliac%20disease%E2%80%94an%20open%20pilot%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=WAHAB,%20P.%20J&rft.date=2000-06&rft.volume=14&rft.issue=6&rft.spage=767&rft.epage=774&rft.pages=767-774&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.2000.00718.x&rft_dat=%3Cproquest_cross%3E71181714%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4728-82cc15b7c14aaf7413e576250206236fbc4edddcb36094cd0aca09305cdf80d13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71181714&rft_id=info:pmid/10848661&rfr_iscdi=true |